StemCell Therapy

TMRR, in its recent market report, suggests that the Stem Cell Therapy market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Stem Cell Therapy market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period.

The Stem Cell Therapy market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Stem Cell Therapy market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Stem Cell Therapy market study provides reliable and authentic projections regarding the technical jargon.

In this Stem Cell Therapy market study, the following years are considered to project the market footprint:

The content of the Stem Cell Therapy market report includes the following insights:

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

On the basis of solution, the global Stem Cell Therapy market report covers the following solutions:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

The Stem Cell Therapy market study answers critical questions including:

All the players running in the global Stem Cell Therapy market are elaborated thoroughly in the Stem Cell Therapy market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Stem Cell Therapy market players.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why choose TMRR?

Continued here:
Stem Cell Therapy Market Opportunity Analysis and Industry Forecast up to 2017 2025 - Jewish Life News

Diabetes is characterized by trouble producing or managing insulin, and one emerging treatment involves converting stem cells into beta cells that secrete the hormone. Now, scientists have developed a more efficient method of doing just that, and found that implanting these cells in diabetic mice functionally cured them of the disease.

The study builds on past research by the same team, led by Jeffrey Millman at Washington University. The researchers have previously shown that infusing mice with these cells works to treat diabetes, but the new work has had even more impressive results.

These mice had very severe diabetes with blood sugar readings of more than 500 milligrams per deciliter of blood levels that could be fatal for a person and when we gave the mice the insulin-secreting cells, within two weeks their blood glucose levels had returned to normal and stayed that way for many months, says Millman.

Insulin is normally produced by beta cells in the pancreas, but in people with diabetes these cells dont produce enough of the hormone. The condition is usually managed by directly injecting insulin into the bloodstream when its needed. But in recent years, researchers have found ways to convert human stem cells into beta cells, which can pick up the slack and produce more insulin.

In the new study, the team improved that technique. Usually when converting stem cells into a specific type of cell, a few random mistakes are made, so some other types of cells end up in the mix. These are harmless, but arent exactly pulling their weight for the job at hand.

The more off-target cells you get, the less therapeutically relevant cells you have, says Millman. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion cells. It makes curing the disease 25 percent more difficult.

So, the new method was focused on reducing those unwanted extras. By targeting the cytoskeleton, the underlying structure that gives cells their shape, the team was able to not only produce a higher percentage of beta cells, but they also functioned better.

Its a completely different approach, fundamentally different in the way we go about it, said Millman. Previously, we would identify various proteins and factors and sprinkle them on the cells to see what would happen. As we have better understood the signals, weve been able to make that process less random.

When these new-and-improved beta cells were infused into diabetic mice, their blood sugar levels were stabilized, rendering the diabetes functionally cured for up to nine months.

Of course, at this stage its just an animal trial, so the results may not translate to humans any time soon, if ever. But the researchers plan to continue the work by testing the cells in larger animals over longer periods, with hopes of one day getting the treatment ready for human clinical trials.

The research was published in the journal Nature Biotechnology.

Source: Washington University

Continued here:
Mice with diabetes "functionally cured" using new stem cell therapy - New Atlas

The study builds on past research by the same team, led by Jeffrey Millman at Washington University. The researchers have previously shown that infusing mice with these cells works to treat diabetes, but the new work has had even more impressive results.

These mice had very severe diabetes with blood sugar readings of more than 500 milligrams per deciliter of blood levels that could be fatal for a person and when we gave the mice the insulin-secreting cells, within two weeks their blood glucose levels had returned to normal and stayed that way for many months, says Millman.

Insulin is normally produced by beta cells in the pancreas, but in people with diabetes these cells dont produce enough of the hormone. The condition is usually managed by directly injecting insulin into the bloodstream when its needed. But in recent years, researchers have found ways to convert human stem cells into beta cells, which can pick up the slack and produce more insulin.

In the new study, the team improved that technique. Usually when converting stem cells into a specific type of cell, a few random mistakes are made, so some other types of cells end up in the mix. These are harmless, but arent exactly pulling their weight for the job at hand.

The more off-target cells you get, the less therapeutically relevant cells you have, says Millman. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion cells. It makes curing the disease 25 percent more difficult.

So, the new method was focused on reducing those unwanted extras. By targeting the cytoskeleton, the underlying structure that gives cells their shape, the team was able to not only produce a higher percentage of beta cells, but they also functioned better.

Its a completely different approach, fundamentally different in the way we go about it, said Millman. Previously, we would identify various proteins and factors and sprinkle them on the cells to see what would happen.

As we have better understood the signals, weve been able to make that process less random.

When these new-and-improved beta cells were infused into diabetic mice, their blood sugar levels were stabilized, rendering the diabetes functionally cured for up to nine months.

Of course, at this stage its just an animal trial, so the results may not translate to humans any time soon, if ever. But the researchers plan to continue the work by testing the cells in larger animals over longer periods, with hopes of one day getting the treatment ready for human clinical trials.

The research was published in the journal Nature Biotechnology.

Continued here:
Mice with diabetes functionally cured using new stem cell therapy - Daily Times

The latest version of the 2020 market study on Cancer Stem Cell Therapy Market comprising 97 with market data Tables, Charts, Graphs, and Figures which are easy to understand with showcased in-depth analysis.

The global Cancer Stem Cell Therapy market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Cancer Stem Cell Therapy by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Check out sample report at: https://www.amplemarketreports.com/sample-request/global-cancer-stem-cell-therapy-market-1351346.html

As per the research and study, the market has settled its presence worldwide. Cancer Stem Cell Therapy Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Glancing to 2020, the global market expected to be a significant year for Cancer Stem Cell Therapy Market in terms of growth and revenue.

Almost all companies who are listed or profiled are being to upgrade their applications for end-user experience and setting up their permanent base in 2020. This report focused and concentrate on these companies including AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

Furthermore, the research contributes an in-depth overview of regional level break-up categorized as likely leading growth rate territory, countries with the highest market share in past and current scenario. Some of the geographical break-up incorporated in the study are AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

With the Cancer Stem Cell Therapy market forecast to expand CAGR% in 2020 and with X-X-X-X supposed to be a big beneficiary, it is better positioned than Z-Z-Z-Z for 2020.

According to the AMR market study, Recent trends in consumer preferences market segments such as type, application will be more challenging. Cancer Stem Cell Therapy market segment sales will traverse the $$ mark in 2020.

Unlike classified segments successful in the industry such as by Type (Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Others) and by End-Users/Application (Hospital, Clinic, Medical Research Institution, Others).

The 2020 version of the Cancer Stem Cell Therapy market study is a further split down / narrowed to highlight the latest emerging twist of the industry.

Enquire more before buy at: https://www.amplemarketreports.com/enquiry-before-buy/global-cancer-stem-cell-therapy-market-1351346.html

Due to a change in consumer preferences with a review on the latest sales and revenue report submissions, Major vendors in the Global market are trying to get the attention of end-users or consumers by Offerings and additional services.

With using the latest technology and analysis on demand-side, Key players are getting in consumer behavior and their changing preferences.

Again, big investment firms or giants are willing to put more capital to get a key players performance in the market for new applications or products.

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/global-cancer-stem-cell-therapy-market-1351346.html

Research Objectives and Purpose

Read More about this report at: https://www.amplemarketreports.com/report/global-cancer-stem-cell-therapy-market-1351346.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at sales@amplemarketreports.com, or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

Go here to see the original:
Global Cancer Stem Cell Therapy Market 2020: What Are The Key Trends In Market? - Chronicles 99

R3 Stem Cell Heroes Program - Free Regenerative Procedures for Veterans

LAS VEGAS (PRWEB) February 20, 2020

R3 Stem Cell, the nation's leader in regenerative therapies and provider training, announced that its Heroes Program was able to complete 70 complimentary stem cell procedures on military veterans in 2019. The veterans traveled from all over the US to receive the regenerative therapies at no cost.

At the R3Stem Cell Training Course for doctors, providers of all kinds learn how to perform regenerative procedures in a supervised setting. This includes stem cell and exosome procedures on military veterans of all ages and from all branches of service. Any veteran can be nominated (or nominate themselves), and the pain being experienced does not have to be a result of a service related injury.

According to R3 Stem Cell CEO David Greene, MD, MBA, "When we hear the stories of these Veterans and what they have done for America, it's so exciting to be able to do something to help improve their quality of life. Especially Veterans of the Vietnam War, all they wanted to do was protect our country. To see how well they do afterwards and then refer in their Veteran friends for procedures, it's amazing!"

The chosen Veterans receive an evaluation by the Board Certified doctors who are trainers, and then procedures include whatever amount of regenerative biologic deemed appropriate. The Veteran patients are followed up the R3 staff, and invited back for additional therapies when necessary.

To date over 70 Veterans have successfully receive regenerative therapies in the program. Over a dozen patients are treated at each workshop, with more opportunities upcoming. Added Dr. Greene, "Our stem cell courses are extremely hands on an providers love it. They have been increasing in popularity continuously, which allows us to treat more Veterans!"

For those who would like to nominate a Veteran for the Heroes Program to receive free stem cell therapy, simply visit https://r3stemcell.com/hero or call (844) GET-STEM.

Share article on social media or email:

See original here:
R3 Stem Cell Heroes Program Performs Complimentary Regenerative Therapies on 70 Veterans in 2019 - PR Web

PITTSBURGH (KDKA) Dr. Mike Hutchinson, DVM performed his first stem cell procedure in 2008. Nearly 12 years later, he can tell you all about his first case.

It was a lab mix. It couldnt get up on this floor. We tried to help it up, and it was having trouble walking so we treated it, says Hutchinson.

Fourteen days later, it came for suture removal, and it was already walking in here. He even put his front feet on the table.

Based on early success stories like that, KDKA-TV featured a 10-year-old German Shepherd named Angel.

When we met her, Angel limped noticeably from arthritis in her hips. After stem cell treatment, the dogs owner Jane Fornear says her beloved pet looked like a new dog.

Within 48 hours, her eyes were clear, explained Fornear.

She had Angel show us how much better she felt: she asked the big shepherd to sit in front of her, then told Angel, Give me your paw.

WATCH: Angels Journey To Recovery

Angel immediately lifted her right paw and put in in Fornears waiting hand about 3 feet off the ground.

Jane released the paw and said, Give me your other paw. Just as quickly, Angel lifted her left front paw off the ground and put it in Fornears other hand.

You could almost hear the tears building in Fornears voice as she petted her dogs face and ears. We couldnt give our paw before because our arms and legs hurt too much, didnt they?

Fast forward to 2014. Panzer is a large breed mix who tore the anterior cruciate ligament in one of his legs.

Dr. Mike told Panzers owner the dog would be a great candidate to use injected stem cells to help speed healing in the joint.

Sharon Germain remembers that conversation like it just happened: I just sat there going really? And I said anything to make things heal better and make him feel better. I was on board immediately.

Seven months after having the ACL repair surgery with stem cells, KDKA was there with Sharon watching Panzer tear through the November snow in Germains backyard like a hyperactive puppy.

Seeing is believing. Its just Germain paused and then let out a big sigh. It just does your heart good to see this. Germain was fully convinced it had worked for her dog.

Since those early surgeries, Hutchinson has never stopped talking about using stem cells to treat animals that are in pain.

In 2015, he told KDKA, Its just rewarding to hear from grateful pet owners over and over and over, said the Ohio State Vet School graduate. Its why I do it.

Panzer lived four years after his initial stem cell treatment. Germain said he never slowed down because his pain was gone.

It was like nothing ever happened to him. It was like he never even had surgery, says Germain. I mean, outside of a little white hair where the surgery incision was made, that was it.

Many other animals have had similar results. Hutchinson has now given stem cells to more than 1,100 animals. Many of the pets are dogs, but he has also worked with race horses as well as racing camels in the Middle East.

WATCH: Panzers Experience With Stem Cells

He has lectured and scrubbed in on stem cell surgeries around the world, Canada, South America, Australia, and across the United States.

Yet the majority of the surgeries are done at his Animal General veterinary practice in Cranberry, Butler County everyday pets like Baxter who had not one, but two torn ACLs.

They were both completely severed, explained Baxters owner Nicole Mountain of OHara Township.

He had no mobility. He had no use of his back legs. My husband Jeff was carrying him outside to use the bathroom.

Baxter is a not a little dog. He is a 95 pound Staffordshire-terrier mix. He tore those knee ligaments in 2014.

Another orthopedic vet repaired the injured joints with a procedure called PTLO surgery. It involved putting metal plates in his back legs. The Mountains were warned that it would be a long and painful recovery for their dog and for them.

(Photo Credit: KDKA)

Mountain agrees saying it was every bit as bad as they warned and then some.

Baxter was moaning in pain, Mountain says. He was pumped up with so much pain medication he was vomiting. He couldnt hold food down. He couldnt move.

Eighteen months later, Baxter was mostly healed from the surgeries, but he was still in significant pain. That is when the Mountains learned of Dr. Hutchinsons use of stem cells.

Nicole was ready to go from the moment she heard about the procedure. Her husband Jeff wasnt exactly sold.

Ill be honest, when Nicole sent us out there, I thought it was crazy. You know, I honestly did, said Jeff Mountain. I said youre sending us to this Voodoo doctor to do this stem cell treatment. I said, Where is it going to stop?'

Mountain had lived through the ordeal of helping Baxter heal from his ligament problems.

My husband was calling from Samsonite because we had one of those Help-Me harnesses, and he was lifting him up and carrying him out like luggage.

When they heard about how other dogs had been helped by stem cells, they decided to give it a try. Dr. Hutchinson recalls the conversation with the Mountains at their initial consultation.

They wanted to know if the stem cells would help the arthritis, and I said thats exactly what I would treat it with. That would be my gold therapy for that so we did that, and that had a very positive response as well. Then we were able to bank some of those cells for the future, recalls Hutchinson.

It didnt take long for the Mountains to see that Baxter was visibly better.

Within about a month, we started to really see him jumping up on counters for treats, said Jeff Mountain. You know, when we went out to walk him, he is back to running.

Mountain said that wasnt the only change she noticed.

He had this almost it sounds almost funny to say he looked very white, she paused to think. It was almost like his eyes were brighter. He was just a brighter dog. He just looked like, there was a visible difference in him.

Dr. Mike has heard it all many times.

People say it looks like their dogs are younger because their eyes are brighter. They are happier. They are in less pain, and thats a great reward for stem cells, explains Dr. Mike.

One of prospective patients first questions is often how much will it cost? When Hutchinson started, each procedure ran about $3,200. Now it has come down to about $1,800.

It can be less than that. The Mountains have a pet insurance on Baxter, and the stem cell therapy was covered by their policy.

I thought it was cost effective too, reflected Jeff Mountain, compared to other things that weve spent money on for surgeries and treatments for the dogs.

Lets go back to Panzer, Sharon Germains beloved dog. He lived nearly four years after surgery, before dying about a year ago. In retrospect knowing what she knows now, would she spend the out-of-pocket money to do stem cell treatment again on her dog?

Absolutely. Absolutely. The best money spent. Without hesitation, says Germain.

The next question: would you do it again for another dog?

Germain didnt even flinch. Absolutely. I would do it again for me.

She knows all about that too. After seeing how well it worked for her dog, she had stem cells injected into her chronically painful knee. Like her dog, she says her pain was gone in a matter of days, and it hasnt come back.

Dr. Hutchinson stresses stem cells are not a cure-all. They cant be used for every ailment, and Hutchinson says that in every lecture he does on stem cells.

I think its incumbent upon all my colleagues to be ethical and pick the right cases, says Hutchinson.

Its not a panacea. Its for certain cases. Neurological dogs, dogs that are falling over, they have nerve damage. Yeah, there might be a stem cell compassionate use for that and that might be able to help that dog, but Im not going to pretend like thats the common case.

How long do they last?

On average, it doesnt last a lifetime and it lasts maybe a year, a year and a half.

Hutchinson stopped for a second, then continued, But thats huge in a dogs life. They have a short life expectancy. So, if we get a year to year-and-a-half of comfort and pain-free time, thats fantastic. Then we can come back and re-treat them, and expect the similar response when we re-treat them.

Baxters mom Nicole Mountain agrees wholeheartedly that his quality of life is much better than it was before stem cells.

He does not get pain medication. He does not get anti-inflammatories, she claims.

He doesnt take anything thats keeping him comfortable. So for us to have something natural that will last ten, eleven months and then we do again, were thrilled with that.

Dr. Mike harvested enough cells from the original procedure on Baxter that they froze enough for multiple follow-up treatments. Because of that foresight, all they have to do is inject the thawed stem cells into Baxter. Those tune-ups cost about $200 per treatment.

Hutchinson cant say enough about what he has learned since his first stem cell surgery in 2008.

I want to do this every day in my practice because Ive been a vet for a long time, 30 plus years, and when you see the kind of results that were seeing, you know it cant be denied that any veterinarian would want to do what Im doing.

View original post here:
They Are Happier. They Are In Less Pain: Butler Co. Vet Uses Stem Cell Therapy To Help Heal Dogs - CBS Pittsburgh

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart.

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction.

Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one, Dr Ban said.

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

In the study, the hiPSC-CMs were injected directly into the border zone of the rats heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart.

We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist, Dr Ban added.

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

Read the rest here:
First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News

Hudson Institute scientists have demonstrated for the first time that umbilical cord stem cells can protect preterm, growth-restricted babies from brain injury.

Up to five-eight percent of pregnancies in Australia are affected by fetal growth restriction (FGR)-a condition which leads to poor growth of an unborn baby.

The mechanical ventilation that these babies need for the first few days of life can have detrimental effects on the developing brain. Many of them are born early (also referred to as preterm or premature), which only exacerbates the risk of brain injury further.

This brain damage often causes long-term developmental problems, and can lead to conditions such as cerebral palsy, behavioural disorders, cognitive deficits and motor developmental delays.

There is currently no treatment which can be used as an early intervention to prevent brain damage of babies with FGR. However, a growing body of evidence suggests that stem cell therapies could be the answer to this problem.

Dr Atul Malhotra and Associate Professor Suzie Miller led a study published in Stem Cell Research and Therapy which investigated the effect of umbilical cord blood stem cells (UCBCs) in a preclinical model of FGR.

Dr Malhotra is a consultant neonatologist at Monash Newborn, Monash Childrens Hospital; a senior lecturer in the Department of Paediatrics, Monash University; and a research fellow at Hudson Institute. Associate Professor Miller is a Deputy Centre Head at Hudson Institute and a senior scientist at the Department of Obstetrics and Gynaecology, Monash University.

The team demonstrated, for the first time, that UCBCs can alleviate the brain damage caused by FGR and being born preterm-a ground-breaking discovery with significant implications for treatment.

Treatment with UCBCs led to a decrease in neuroinflammation, oxidative stress, cerebrovascular resistance (obstruction to blood flow), and greater integrity of the neurovascular unit in the brain.

The team believe that UCBCs stabilise the neurovascular unit-comprising of several different cell structures that control blood flow to the brain-possibly by reducing the inflammation surrounding them.

These UCBCs therefore act by strengthening the gate keepers of the brain, which in turn mitigates the effects of brain injury caused by an early and growth restricted birth.

We propose that the results of this study lay the foundation for a novel therapeutic option, using cord blood stem cells as an early intervention therapy for these vulnerable babies, commented Dr Malhotra.

Cell therapy is now ready for translation to clinical trials and this study provides further evidence of its potential benefit in preterm infants.

The teams next step is therefore a clinical trial of cord blood therapy in preterm babies at Monash Childrens Hospital, testing feasibility and safety of the treatment.

FGR is a condition where an unborn baby, or fetus, is smaller than expected

It can begin at any time during pregnancy, and puts babies at risk of loss in brain development, which can cause the child long-term problems in later life such as cerebral palsy, autism, learning and other behavioural challenges

Factors in the mother such as high blood pressure, diabetes, cigarette smoking and alcohol or drug use can increase the risk of FGR

The risk can also be increased by the placenta not attaching well, or blood flow through the umbilical cord being limited

Collaborators

Monash University.

Funders

National Health and Medical Research Council (NHMRC), Cerebral Palsy Alliance, The Royal Australasian College of Physicians.

Originally posted here:
Protecting growth-restricted babies from brain injury with stem cell therapy - Mirage News

Arthritis is an umbrella term for a number of conditions that cause swelling and tenderness of one or more of the joints. Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. There's no cure for arthritis, but there are many treatments that can help slow it down and maintain quality of life, including this unusual one.

Osteoarthritis mainly affects the hands, spine, knees and hips, whereas rheumatoid arthritis usually affects the hands, feet and wrists.

Experts are researching ways to use stem cells therapy to help treat arthritis in the knee and other joints.

Many doctors already use stem cell therapy to treat arthritis, but it is not considered standard practice, with some even calling the treatment controversial.

READ MORE: Joe Swash health: I had to learn everything again Actors scary virus

There is a lot of debate around stem cell treatment and it is helpful for potential patients to understand what stem cells are and the issues surrounding their use in arthritis therapy.

How the treatment could help is by reducing inflammation in the body.

In arthritis, the immune system mistakenly attacks the tissue that lines the joints, which causes pain, inflammation, swelling and stiffness.

By reducing inflammation, stem cell therapy increases the presence of healthy cells in the body.

DONT MISS

And it would seem that stem cell therapy has sparked some interest from the royal family.

Princess Michael of Kent, the wife of the Queens cousin Prince Michael, recently appeared in a slick promotional video for a clinic in the Bahamas that offers similar joint therapy.

Look at that, the Princess declares proudly in the five-minute film, holding her right arm high above her head after stem-cell injections for a painful shoulder.

"Its amazing I think stem cells are the future, theres no doubt in my mind."

A stem cell is a type of cell not specialised to perform a specific role.

Instead, it has the unique ability to develop into one of many different types of cell. Stem cell therapy uses stem cells to replace dead and diseased cells within the body.

The human body contains over 200 different types of cell. Usually, each type has certain characteristics that allow it to preform a specific role.

Cells with similar roles group together to form tissues, which then organise to form the bodys organs.

Scientists source the stem cells from body tissue, either from an embryo or an adult human and isolate them in the laboratory.

After manipulating the cells to develop into specific types, they then inject the cells into the recipients blood or tissue.

Researchers are still investigating ways of using stem cells to control inflammation and regenerate damaged tissues.

Mesenchymal stem cells (MSCs) are types of stem cell that can develop into cartilage and bone. Synovial MSC therapy involves injecting these cells directly int the tissues surrounding the affected joints.

Some research shows that MSCs are also able to suppress the immune system and reduce the bodys inflammatory response.

This makes MSC therapy a promising treatment option for autoimmune conditions such as arthritis.

But for all the positive evidence supporting the treatment, it remains hugely controversial.

Most specialists say there is little robust evidence to show it works and it has not been approved by the UK medicines regulator, the National Institute for Health and Care Excellence. Leading health experts most standard approaches to treating arthritis is advising patients to lose weight and get more exercise.

In the US, Google has banned all advertising for products that contain stem cells or another regenerative therapy which uses blood cells, known as platelet-rich plasma, or PRP, because regulators describe the treatments as "new and exploratory".

And in the UK, experts have rubbished claims that Lipogems can treat arthritis.

Professor Chinmay Gupte, consultant orthopaedic surgeon and senior lecturer in knee surgery at Imperial College London, warns: These are extremely expensive treatments, and largely unproven. The problem is when youre desperate, youll try anything.

Read the rest here:
Arthritis treatment: A controversial treatment promoted by a certain royal could help - Express

KEY POINTS

Arthritis is one of the most painful diseases around. Patients would often be taking pain relievers just to combat pain. There are those who seek doctors and are given over-the-counter medications, and there are also those who go the natural means. One royal is promoting a certain kind of treatment, and while the said treatment may have been dubbed as a controversial one, health experts say that it might just help.

The Use of Stem Cells

Stem cell treatment may be the next big thing when it comes to treating arthritis. As per Express report, a lot of doctors have already started using stem cell therapy to treat the debilitating disease. Although it is not considered as a standard practice, with many calling the treatment as controversial, it would seem that more people are going this way. stem cell treatment arthritis Photo: darkostojanovic - Pixabay

This type of treatment reduces inflammation in the body. When inflammation is kept at bay, pain is likewise reduced, allowing patients to suffer less from the disease. This kind of therapy helps in increasing the number of healthy cells.

The Royal Princess

According to the report of Express, Princess Michael of Kent, the wife of Prince Michael, who is the Queens cousin, recently appeared in an ad. In the said promotional video, the Princess was showing her right arm, signifying that stem cells are the future.

She had stem cell injections for the painful shoulder. The video was for a clinic in the Bahamas that offers the arthritis stem cell treatment.

Stem Cell and Arthritis

Researchers are still looking for ways on how to use stem cells to regenerate tissues and to control inflammation. The mesenchymal stem cells (MSCs) are the types of stem cells that develop into cartilage and bone. This has shown great promise in treating arthritis.

Despite the positive responses that the treatment has, there are still those who doubt it and would consider it as controversial. As for those who have benefited from the treatment, maybe stem cells did wonders for them. It could be an avenue for those who are still looking for effective arthritis treatment.

Read the rest here:
Arthritis Treatment: One Royal Is Promoting A Certain Kind Of Treatment - International Business Times

The Stem Cell Therapy Market report 2020-2026 provides a comprehensive analysis of the current market for Smart Camera. It determines the market size of Stem Cell Therapy and also determines the factors that control market growth. The report begins with a basic overview of the Stem Cell Therapy industry and then goes into the Details of the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

The Stem Cell Therapy market report provides detailed information on key factors, Opportunities, Challenges, industry trends and their impact on the market. The market report Stem Cell Therapy also includes company data and its operation. This report also contains information about the pricing strategy, brand strategy and target customer of the Stem Cell Therapy market. It also provides the distributors/dealer list offered by the company. This research report also deals with the main competition, the market development with forecast of the expected years and the expected growth rates. The main factors that drive and influence growth market data and analysis come from a combination of primary and secondary sources.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=JLN&utm_medium=002

[Note: our free sample report provides a brief introduction to the table of contents, table of contents, list of tables and figures, competitive landscape and geographic segmentation, as well as innovations and future developments based on research methods.]

The top Manufacturer with company profile, sales volume, and product specifications, revenue (Million/Billion USD) and market share

Global Stem Cell Therapy Market Competitive Insights

The competitive analysis serves as a bridge between manufacturers and other participants that are available on the Stem Cell Therapy Market. The report includes a comparative study of Top market players with company profiles of competitive companies, Stem Cell Therapy Market product innovations and cost structure, production sites and processes, sales details of past years and technologies used by them. The Stem Cell Therapy Market report also explains the main strategies of competitors, their SWOT analysis and how the competition will react to changes in marketing techniques. In this report, the best market research techniques were used to provide the latest knowledge about Stem Cell Therapy Market to competitors in the market.

Global Stem Cell Therapy Market Segmentation information

The report provides important insights into the various market segments presented to simplify the assessment of the global Stem Cell Therapy Market. These market segments are based on several relevant factors, including Stem Cell Therapy Market product type or services, end users or applications and regions. The report also includes a detailed analysis of the regional potential of the Stem Cell Therapy Market, which includes the difference between production values and demand volumes, as well as the presence of market participants and the growth of each Region over the given forecast period

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=JLN&utm_medium=002

Stem Cell Therapy Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Stem Cell Therapy markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Stem Cell Therapy industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Stem Cell Therapy industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Stem Cell Therapy industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Stem Cell Therapy industry.

Market Dynamics: The report offers deep insights into the dynamics of the Stem Cell Therapy industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Stem Cell Therapy industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Stem Cell Therapy industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Stem Cell Therapy industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Stem Cell Therapy industry.

What will you find out from the global Stem Cell Therapy Market Report?

The report contains statistical analyses of the current and future Status of the global Stem Cell Therapy Market with a forecast to 2026.The report contains detailed information on manufacturers, Stem Cell Therapy Market raw material suppliers and buyers with their trade outlook for 2020-2026.The report informs you about the most important drivers, technologies and Trends that will shape the global Stem Cell Therapy Market in the near future.The report added an exclusive market segmentation, broken down by Product Type, Stem Cell Therapy Market end user and Region.The strategic perspectives on Stem Cell Therapy Market Dynamics, current production process and applications.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=JLN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

Read the original here:
Stem Cell Therapy Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 - Jewish Life News

Global Marketers.biz has published an innovative statistics of the market titled as Stem Cell Therapy Market. To clarify the various aspects, the analyst studies and elaborates the terms by using qualitative and quantitative research techniques. Finance teams can use a variety of corporate planning applications to fulfil the budgeting, planning & financial modelling, needs of their organization, whatever its size, industry and location.

Download Exclusive Sample of Stem Cell Therapy Markets Premium Report at: https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #request_sample

Graphs, tables, bar graphs and pie charts have been represented in sophisticate manner for the clients to better understand the analysis. To enlarge the businesses, customers get increased rapidly through Stem Cell Therapy industry techniques.

Leading Establishments (Key Companies): Osiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCRPharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Different regions, such as Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey and GCC Countries are focused to give the summarized data about the production of Stem Cell Therapy market.

The global Stem Cell Therapy Market is served as a backbone for the enlargement of the enterprises. To address the challenges, the report examines different key factors such as drivers and opportunities. Restraints are considered for evaluation of risk in market.

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and analyses the market trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Global Marketers.biz have segmented the Stem Cell Therapy market on the basis of type, end-user and region:

Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #inquiry_before_buying

Type Outlook (Revenue in Million USD; 20152026)

AutologousAllogeneic

End Use Outlook (Revenue in Million USD; 20152026)

Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Stem Cell Therapy Market Summary: This report includes the estimation of market size for value (million US$) and volume. Estimation methodology validate the market size of Stem Cell Therapy industry, to estimate the size of various other dependent submarkets in the overall market. Secondary research is used to identify the top players in the market, and their market shares have been determined through primary and secondary research. Each type is studied based on classification as Sales, Stem Cell Therapy Market Share (%), Revenue (Million USD), Price and Gross Margin.

Report Objectives:

Target Audience:

Table of Content:

To know More Details About Stem Cell Therapy Market research Report @: https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #table_of_contents

***Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

View post:
Stem Cell Therapy Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Jewish Life News

The Research Report on Stem Cell Therapy marketis a Skillful and Deep Analysis of the Present Situation and Challenges. Experts have studied the historical data and compared it with the current market situation. The Research Reportcovers all the necessary information required by new market entrants as well as the existing players to gain a deeper insight into the market.

Moreover, the research study focuses on the product specifications, diversification, price, cost, production capacity, distribution channel, list of the distributors, and a profound analysis of the import and export data of the product. Upstream raw materials, downstream demand analysis together with the cost, supplier, and consumer list of this market have been examined consistently; product flow and marketing channel have been mentioned as well.

Get a Sample Copy of this Report @:https://www.reportsmonitor.com/request_sample/853193

TheMajor Manufacturers Covered in this Report:Osiris Therapeutics, Inc., Medipost Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, Jcr Pharmaceuticals Co., Ltd., Nuvasive, Inc., Rti Surgical, Inc., Allosource

The research study focuses on

Type Segmentation (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy)Industry Segmentation (Musculoskeletal Disorders, Wounds And Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases)

On the basis of geographical segmentation, the report has been categorized into some of the major regions, with production, generation, revenue, usage, aggregate share and the development rate of the market in these geographies over the forecast period, including North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Regional Segmentation:

Speak to our industry expert and avail discount on Market [emailprotected]https://www.reportsmonitor.com/check_discount/853193

Some of the Points cover in Global Stem Cell TherapyMarket Research Report is:

Chapter 1: Overview of Global Stem Cell TherapyMarket (2020 2024) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers (2020 2024) Raw Material and Suppliers Manufacturing Process Industry Chain Structure.

Explore Full Report with Detailed TOC, Charts, Tables and [emailprotected]https://www.reportsmonitor.com/report/853193/Stem-Cell-Therapy-Market

The key takeaways from the report:

Contact Us:Jay MatthewsDirect: +1 513 549 5911 (U.S.), +44 203 318 2846 (U.K.)Email: [emailprotected]

Go here to read the rest:
Stem Cell Therapy Market Is Changing Drastically? What If History Is Any Guide 2020-2024 | Osiris Therapeutics, Inc., Medipost Co. etc. - Science...

CALGARY, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Hemostemix Inc. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Ronnie Hershman, M.D., F.C.C.S., to its Board of Directors. Dr. Hershman is a successful, practicing cardiologist with over three decades of experience. Dr. Hershman graduated Magna Cum Laude from the Sophie Davis Center for Biomedical Research in 1980 and received his medical degree from Mount Sinai Medical Center in 1982. He then continued his medical and cardiovascular training at Mt. Sinai Medical Center.

Dr. Hershman has been an Invasive Cardiologist since 1987 and was involved in many clinical trials for emerging catheter technologies. He was a pioneer in performing laser-assisted coronary angioplasty, starting in private practice on Long Island in 1989. Presently the Medical Director of NYU Langone Long Island Cardiac Care he built and manages a large medical practice, employing cutting-edge technology and continues his practice for patients with cardiovascular and peripheral vascular diseases, employing a non-invasive therapy for patients with intractable Angina and Congestive Heart Failure.

Dr. Hershman has also been an entrepreneur and investor for more than two decades. He has been involved in life science investing and consulting for several years and previously or currently serves on the boards of medical biotechnology companies Solubest, Ltd., TheraVitae Inc., Nasus Pharma, SanoNash and Optivasive. He also serves as an advisor to a latestage, life science venture capital company that has funded 24 companies to-date. Dr. Hershman is now an investor in OurCrowd, Ltd., a leading crowd funding company and is the Co-Founder and CEO of HealthEffect, LLC and CLiHealth, LLC, SoLoyal and Nasus Pharma along with SanoNash.

Dr. Hershman continues to evaluate new medical technologies in the USA and Israel. His main interests lie in bringing improved medical technologies from the bench to the clinic, quickly and globally. He is actively seeking to commercialize technologies that improve lives and cure illnesses in the most effective and cost efficient manner.

Stem Cell therapies are the future in so many chronic illnesses and Hemostemix is an exciting company with a lot of promise in providing solutions and therapeutic options for many patients with critical Cardiovascular illnesses and ischemia, commented Dr. Hershman. As an investor and Board Member, I hope to assist in advancing these therapies further and create optimal value for patients and shareholders, alike, he said.

Dr. Hershman is replacing Mr. Yari Nieken and Mr. Bryson Goodwin who both resigned from their positions with the Company effective February 10, 2020. Ms. Natasha Sever has also resigned from the position of CFO. The Company will look for suitable replacements for both CEO and CFO positions and Mr. Smeenk will act as the interim CEO until a replacement is hired. The Company thanks Bryson, Yari and Natasha for their service and wishes them well in their future endeavors.

It is a great pleasure to welcome Dr. Hershman to the Board of Directors, said David Wood, Chairman, as he compliments us with his broad medical experience, biotechnology and business investment acumen and counsel.

I am honored and delighted to welcome Dr. Hershman to the Board of Directors and I very much look forward to his counsel, said Thomas Smeenk, President.

The Company also announces that on January 9, 2020, J.M. Wood Investment Inc. (JMWI) sent the Company a Notice of Default and Demand for the immediate repayment of the Companys previously announced convertible debenture and demand loan. Based on the repayment conditions of the debts, the Company took the position the January 9th notice was premature. On January 24th, JMWI made an application to the Court of Queens Bench of Alberta for the issuance of an order appointing a receiver. The Company responded with a 347 page affidavit including appendices, sworn on January 30th by David Wood, Chairman. The application was heard on January 31st by Madame Justice Horner, who granted a consent order to adjourn the JMWI receivership application to February 20, 2020 to enable the Company to close its financing; granted an order appointing Grant Thornton as inspector; granted an order that the costs of the application of January 31st would only be payable by the Company if the application proceeds on February 20th. On February 6, 2020 cross examinations on the Affidavits of David Wood and JMWI were heard.

Story continues

Also, on February 3, 2020 the Company received an action from Aspire Health Science, LLC filed with the Ninth Judicial Circuit Court for Orange County, State of Florida, in connection with the Amended and Restated License Agreement rescinded by Hemostemix on December 5, 2019 due to Aspires failure to meet the Condition Precedent of paying US$1,000,000 within 30 business days of September 30, 2019. The Company believes the action is frivolous, without merit, and it intends to vigorously defend its position.

The Company intends to effect repayment of the secured debts and it will provide a further update to the market at that time. Although the Company is optimistic that it will be successful in raising sufficient funds to meet its obligations, there can be no assurance that the financing will close as anticipated or within the time frames required.

ABOUT HEMOSTEMIX INC.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other heart conditions. ACP-01 has been used to treat over 300 patients, including no-option end-stage heart disease patients, and it has been the subject of four open label phase II clinical studies which proved its safety and efficacy.

On October 21, 2019, the Company announced the results from its presentation from its Phase II CLI trial abstract presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Companys clinical trial for CLI is ongoing at 20 clinical sites in North America and 56 of 95 subjects have been enrolled to-date.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact:

Thomas Smeenk, President & CEO Suite 1150, 707 7th Avenue S.W.Calgary, Alberta T2P 3H6Tel: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential, and similar expressions, or that events or conditions will, would, may, could, or should occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companys ability to fund operations and access the capital required to continue operations and repay its secured debts, the Companys stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Companys markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Companys operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Companys filing with the Canadian securities regulators, which filings are available at http://www.sedar.com.

Excerpt from:
Hemostemix Announces the Appointment of Dr. Ronnie Hershman to the Board of Directors and Provides a Corporate Update - Yahoo Finance

SAN ANTONIO, Feb. 3, 2020 /PRNewswire/ -- SASpine is now offering cutting edge Stem Cell Treatments to patients. For the past several years Dr. Steven Cyr, Mayo Clinic Trained Spine Surgeon, has been researching the benefits of stem cells in the treatment of multiple medical conditions including spinal disorders, specifically, conditions which involve spinal cord injury, degenerative disc disease, herniated discs, and as a supplement to enhance the success of Spinal fusions when treating instability, deformity, and fractures of the spine.

Steven J. Cyr, M.D., is a spine surgeon who has gained a reputation for surgical excellence in Texas, throughout the nation, and abroad.

Dr. Steven Cyr has been treating patients using growth factors and stem cells contained in amniotic tissue and bone marrow aspirate to provide a potential for improved success with fusion procedures, when treating herniated discs, and for arthritic or damaged joints, with remarkable success. "The goal of any medical intervention is to yield improved outcomes with the ideal result of returning a patient to normal function, when possible," states Dr Cyr. He went on to elaborate that there are times when only a structural solution can solve problems related to spinal disorders, but even in that scenario, the use of stem cells or growth factors derived from stem cell products can possibly improve the success of surgical procedures. "I have patients previously unable to jog or run return to normal function and athletic ability after injections of growth factors and stem cell products into the knee joints, hip joints, and shoulder joints," he said. "This includes high-level athletes, professional dancers, and the average weekend warrior."

There may be promise in treating patients with spinal cord injury as well. SASpine CEO, LeAnn Cyr, states, "There are reports of patients gaining significant neurological improvement after being treated with stem cells." Dr Cyr continues, "Most patients with spinal cord injuries resulting from trauma also have mechanical pressure on the nerves that result either from bone fragments or disc material compressing the spinal cord that needs to be removed along with surgical stabilization of the spinal bones. There's significant potential that stem cells bring to the equation when treating these types of patients, and I am excited about the potential that these products offer to the host of treatments to address spinal conditions and arthritic joints."

For more information about SASpine's Stem Cell Treatment Program, visit http://www.saspine.com or call (210) 487-7463 in San Antonio or (832) 919-7990 in Houston.

Related Linkswww.facebook.com/saspinewww.instagram.com/surgical.associates.in.spine

If you've been living with back pain, you're not alone. Here at SASpine, we have experienced spine specialists who are committed to improving your quality of life. (PRNewsfoto/SASpine)

View original content to download multimedia:http://www.prnewswire.com/news-releases/saspine-to-offer-stem-cell-therapy-300997355.html

SOURCE SASpine

Go here to see the original:
SASpine to offer Stem Cell Therapy - Yahoo Finance

Published 7:30am EST, Monday, February 3, 2020

Bridges by EPOCH at Trumbull, a memory care assisted living community, located at 2415 Reservoir Ave., will host the following complimentary events in February. Call 203-935-8530 to RSVP.

Dementia Live Experience Thursday, Feb. 6, from 4 to 8 p.m. Presented by Right at Home, Caregivers are invited to reserve a time slot to step inside the body and mind of dementia. This powerful virtual experience will allow caregivers to see, hear and feel what life is like for someone living with dementia. Caregivers may bring their loved ones with memory loss to enjoy an activity with Bridges residents during this seminar. Refreshments will be served.

Caregiver Support Group Wednesday, Feb. 19, at 5:30 p.m. Caregivers are invited to trade tips, socialize with others on a similar journey and receive expert advice from dementia care professionals who understand their challenges and concerns. Dinner will be served. Caregivers may bring their loved ones with memory loss to dine with Bridges residents while they attend the group.

Dine and Discover Stem Cell Therapy for Stroke and Traumatic Brain Injury (TBI) Patients: Thursday, Feb. 20, at 5 p.m.; With Guest Speaker Dr. Peter McAllister, co-founder and Chief Medical Officer, New England Institute for Clinical Research. Stroke and traumatic brain injury strike millions of people each year. Dr. McAllister will discuss the various treatment options for the long-term effects of these conditions, including weakness, spasticity, language and cognitive difficulties and pain. He'll also discuss new research on stem cell therapy that could help restore function for stroke and TBI patients. Caregivers may bring their loved ones with memory loss to enjoy a meal and an activity with Bridges by EPOCH residents during this seminar. Dinner will be served.

See more here:
Dementia Live and 'Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients' seminars - Trumbull Times

NASSAU, BAHAMAS The fate of Freeports pioneering stem cell therapy provider has now become the subject of legal dispute, with its principal creditor seeking the winding-up of the company.

According to court documents seen by Eyewitness News, Okyanos claims that damagessuffered toits nearly 15,000 sq feet rented Freeport facilities as a result of Hurricane Dorian in September 2019 left thepremisesunfit for use. As a consequence, all of thecompanysbusiness ceased. That claim however has beenfiercely disputed by its landlord First Commercial Ltd who is seeking to have its dispute arbitrated and block the removal of the companys equipment which could satisfy an award in those proceedings.

Okyanos is the first licensed stem cell therapy provider in The Bahamas. It has been treating patients with chronic diseases by using their own stem cells from fat tissue. It opened to patients in October 2014, providing treatment for those with autoimmune, orthopaedic, cardiovascular and neurological conditions.

According to details outlined in a wind-up petition by its primary creditor LS Enterprise Ltd, -a companyregisteredin the British Virgin Islands, Okyanos between August 2, 2017 and May 6 2019 entered into four loanfacilityagreementsfor working capital and generalcorporate amounting to some $15.9 million. Okyanos had ultimately sought additional loans from LS Enterprise Ltd following Hurricane Dorian however was informed that it was in default of its facility agreements having ceased to carry on its business and that all loans were immediately due and payable.

According to the wind-up petition an ex parte order obtained by Okyanoss landlord First Commercial Ltd had restrained the stem cell therapy provider fromremediatingthepremisesor removing its equipment. It is claimed that substantial amounts of water and wind had penetrated the companyspremises causing major property loss and damage.Further, a lack of consistent electricity and airconditioninghad caused mold contamination.

Thecompanyattemptedtomitigateloss and damage by movingequipmentto aclimatecontrolledstorage and and preparing thecompanysoperatingfacilitiesfor moldremediation butthat was hampered by the landlord whose servants oragentsinstructed thecompanys personnel to cease anddeistfrom such activities, LS Enterprise outlined in its petition.

It further noted that in a notice to the landlord dated October 25, 2019, Okyanos had exercised its right to terminate its leaseagreementwithin 60 daysfollowingthe storm due to the facilities being unfit for use or occupancy the hurricane. On October 30, First Commercial Ltd obtained an ex parte order restraining the company from anyfurtherremediation efforts as well as the removal or disposal of equipment, LS Enterprise has claimed. The company had filed for damages with its insurance provider but had not received the majority of any such insurance proceeds the petition station.

Accordingly it is claimed that the company has insufficient funds to secure a new lease forfacilitiesto treatpatients,arbitratewith landlord torecover itsequipment and supplies, or conduct amarketingcampaignto attract patients to The Bahamas.

However, an affidavit but attorney Andre Jay Feldman, president and a member of the Board of Directors of First Commercial Centre seeking to restrain Okyanos from breaching its lease disputed the companys damages claim.

According to Mr Feldmans affidavit, a copy of which was seen by Eyewitness News, he inspected thepremiseson September 4 and beyond some minimal damage due to a single window having opened in one of theclinicalrooms, there was no damagewhatsoeverthroughoutthe clinic and nosignificantdamage referred to by the company. Mr Feldman claimed that Steve Araiza, a Houston based attorney for Okyanos had written him on September 26, 2019 seeking a rent abatement and to end theleaseon thegrounds of hurricane damage.

According to Mr Feldman, flood water had entered parts of theground flooroccupiedby CIBC and on September 15, 2019, the bank had not onlyremediatedany damage but hadreopenedfor business. He further contended that on September 4, Okyanos had allowed the Rand Memorial Hospital to use itsfacilities for urgent patient care. Mr Feldman contends that there was no damage to make the facilities unfit for use. According to Mr Feldman, since September 1 there had been no payment towards rent or electricity with respect to air-conditioning consumption. He asserted that if Okyanos is allowed to remove its assets they would be shipped out of country and would not be available to satisfy any award from arbitration. The landlord is claiming it is owed $1,768,000 and that while it plans to claim on a $890,000 loss of rentinsurancethere is no guarantee that can be recovered.

Original post:
Freeport stem cell therapy provider Okyanos in wind-up petition battle - EyeWitness News

Gilbert, Arizona based alternative medicine specialist Dr. Farid Rooh launched a new webinar on stem cell therapy, exosome injections, and other regenerative medicine therapies for chronic pain.

(Newswire.net -- February 3, 2020) -- Gilbert, AZ -- Gilbert, Arizona based alternative medicine specialist Dr. Farid Rooh launched a new webinar on stem cell therapy, exosome injections, and other regenerative medicine therapies for chronic pain.

Dr. Farid Rooh-Parvar DPSc, BCIM of Wellness 1st Integrative Medical Center in Gilbert, Arizona, announced a new webinar on the most effective regenerative medicine therapies for chronic and acute pain, arthritis, sciatica and other conditions.

More details can be found at http://bit.ly/2L8DNxY.

The newly released webinar aims to answer a series of important questions related to the most effective ways to address pain resulting form a variety of musculoskeletal conditions.

Dr. Rooh discusses the numerous applications of research-based regenerative medicine on countless patients who have seen important improvements in terms of pain relief, improved function and mobility.

The new webinar includes a detailed look at therapeutic approaches including stem cell therapy, exosome injections, amniotic tissue, adipose tissue and bone marrow therapies and more.

The focus is on helping viewers get a basic understanding on how the latest innovations in alternative, holistic and regenerative medicine can help patients suffering from a diverse range of health issues.

The webinar provides essential insights into the applications of regenerative medicine for the treatment and management of neck, back, shoulder and join pain, sciatica, arthritis, tennis elbow, loss of feeling in feet and other conditions.

All approaches are based on identifying and addressing the root cause of the patients health issues, rather than simply alleviating the symptoms.

With the latest announcement, Dr. Rooh continues to expand his range of high-quality alternative and regenerative medicine resources for patients in Arizona and beyond.

An experienced practitioner specializing in holistic and alternative medicine, Dr. Rooh offers personalized treatments for patients in Gilbert, Chandler and the surrounding areas of Arizona.

A satisfied patient said: As a new patient I was beyond impressed with this medical facility. During my consultation the kind and approachable Dr. Rooh met with me then his outstanding case manager Casi spent time with me exploring my options for a treatment plan that best suits my needs and situation. I can't express what a wonderful experience this was and I am so excited to be a new patient of theirs.

Interested parties can find more information by visiting the above-mentioned website.

See the rest here:
Stem Cell Pain Relief No Surgery Regenerative Therapy Webinar Released - Newswire

Exosome Diagnostics Market Report analysis including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis for upcoming years.

ReportsnReports added a new report on The Exosome Diagnostics Market Technologies report delivers the clean elaborated structure of the Report comprising each and every business related information of the market at a global level. The complete range of information related to the Exosome Diagnostics Market Technologies is obtained through various sources and this obtained the bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade based study regarding the Exosome Diagnostics Market Technologies.

Download a Free PDF Sample of Exosome Diagnostics Market Technologies Research Report at:

http://www.reportsnreports.com/contactme=1781607

Top Companies mentioned in this report are Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell Medicine Ltd, Tavec Inc, Codiak Biosciences Inc, Therapeutic Solutions International Inc, ArunA Biomedical Inc, Ciloa 85.

This latest report is on Exosome Diagnostics Market Technologies which explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy.

Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intracellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biological vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

Reasons to buy this Report:

Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector, Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies, Identify trends in interventional and observational clinical trials relevant to exosomes.

Get this Report @ http://www.reportsnreports.com/purchasme=1781607

Scope of this Report:

What are the features of the exosome lifecycle?,How are therapeutic exosomes prepared?,How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?,Which companies are investing in exosome technologies?,How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Table of contents for Exosome Diagnostics Market Technologies:

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Exosomes in Healthcare 8

2.1 Overview of Exosomes 8

2.2 Drug Delivery Systems 9

2.2.1 Modified Release Drug Delivery Systems 9

2.2.2 Targeted Drug Delivery Systems 10

2.2.3 Liposomes 12

2.2.4 Viruses 14

2.2.5 Exosomes 17

2.3 The Exosome Lifecycle 18

2.4 Exosomes in Biology 18

2.5 Exosomes in Medicine 19

2.5.1 Biomarkers 19

2.5.2 Vaccines 20

2.6 Exosomes as a Therapeutic Target 20

2.7 Exosomes as Drug Delivery Vehicles 21

2.8 Therapeutic Preparation of Exosomes 21

2.8.1 Isolation and Purification 22

2.8.2 Drug Loading 22

2.8.3 Characterization 23

2.8.4 Bioengineering 23

2.8.5 Biodistribution and In Vivo Studies 23

2.8.6 Advantages of Exosome Therapies 24

2.8.7 Disadvantages of Exosome Therapies 24

2.9 Exosomes in Therapeutic Research 25

2.9.1 Exosome Gene Therapies 25

2.9.2 Exosome in Stem Cell Therapy 26

2.10 Exosomes in Oncology 27

2.10.1 Immunotherapy 27

2.10.2 Gene Therapy 28

2.10.3 Drug Delivery 29

2.10.4 Biomarkers 30

2.11 Exosomes in CNS Disease 30

2.11.1 Tackling the Blood-Brain Barrier 30

2.11.2 Exosomes in CNS Drug Delivery 31

2.11.3 Gene Therapy 32

2.12 Exosomes in Other Diseases 33

2.12.1 Cardiovascular Disease 33

2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

3.1 Overview 36

3.2 Exosome Pipeline by Stage of Development and Molecule Type 36

3.3 Pipeline by Molecular Target 37

3.4 Pipeline by Therapy Area and Indication 38

3.5 Pipeline Product Profiles 38

3.5.1 AB-126 - ArunA Biomedical Inc. 38

3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39

3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39

3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39

3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39

3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39

3.5.7 Biologics for Prostate Cancer - Cells for Cells 40

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40

3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41

3.5.10 CIL-15001 and CIL-15002 - Ciloa 42

3.5.11 ExoPr0 - ReNeuron Group Plc 42

3.5.12 MVAX-001 - MolecuVax Inc. 43

3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44

3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44

3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

4.1 Interventional Clinical Trials 48

4.1.1 Clinical Trials by Therapy Type 48

4.1.2 Clinical Trials by Therapy Area 49

4.1.3 Clinical Trials by Stage of Development 50

4.1.4 Clinical Trials by Start Date and Status 50

4.2 Observational Clinical Trials 51

4.2.1 Clinical Trials by Therapy Type 51

4.2.2 Clinical Trials by Therapy Area 51

4.2.3 Clinical Trials by Stage of Development 52

4.2.4 Clinical Trials by Start Date and Status 53

4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

5.1 Company Profiles 67

5.1.1 Capricor Therapeutics Inc. 67

5.1.2 Evox Therapeutics Ltd 72

5.1.3 ReNeuron Group Plc 73

5.1.4 Stem Cell Medicine Ltd 77

5.1.5 Tavec Inc. 78

5.1.6 Codiak Biosciences Inc. 80

More here:
Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies - WhaTech...

The Indian Psychiatric Society (IPS) the professional body that represents psychiatrists in India, strongly condemned the use of stem cell therapy in psychiatric disorders, particularly autism, until such a time that research evidence substantiated its effectiveness.

IPS, in its position statement on stem cell therapy on January 17, said that till now, there is no scientifically validated and scrutinized research evidence that proves that stem cells are helpful in any psychiatric disorders including autism.

Autism is a complex neurodevelopmental disorder with no known single cause.

The advisory from the IPS comes at a time when stem cell therapy clinics that claim to have developed stem cell therapies to treat complex psychiatric problems such as autism, cerebral palsy (movement disorder), muscular dystrophy (weakness of muscles), mental retardation, spinal cord injury and brain stroke have mushroomed across the country.

These stem cell therapy centres extract stem cells from the bone marrow of each child and then inject it into the childs spinal canal. The whole procedure takes place under general anaesthesia.

These clinics use aggressive marketing techniques and false claims to lure parents of children who are suffering from disease like autism.

The Indian Council of Medical Research (ICMR) has already published guidelines that cover the various diseases that are applicable for stem cell treatment. No psychiatric disorders, including autism, are listed there under this advisory.

Stem cells are special human cells that have the ability to develop into many different cell types, from muscle cells to brain cells. In some cases, they also have the potential to repair damaged tissues, and provide a cure for various diseases. But the clinical evidence at this point is low.

Psychiatric disorders including autism are combined derangements of both neurodevelopmental and neurodegenerative trajectories of brain and are polygenetic in origin. So they actually are symptomatic manifestations of a variety of different pathogenetic processes about which scientific evidence is as yet inconclusive, IPS said.

Read more:
Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com